Abstract
Background: Gefitinib is effective in patients with lung adenocarcinoma. Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma. Methods: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known. Tumour response and survival were evaluated and stratified by smoking status and gender. Results: Among the 260 patients, 157 were male (60%). Median pack-years was 40 (range 8-160) and 23 (range 1-74) in male and female smokers, respectively. Objective response was observed in 62 (23.8%) of the 260 patients, and 1-year overall survival and progression-free survival were 45.1 and 24.3%, respectively. Multivariate analysis revealed that smoking status (pack-years) was an independent predictive factor for response to gefitinib [odds ratio (OR) = 0.971, 95% confidence interval (CI) = 0.947-0.995; P = 0.0159] in male patients, but not in female patients (OR = 0.999, 95%CI = 0.957-1.042). Additionally, pack-years significantly influenced the overall survival in males (hazard ratio = 1.010; 95%CI = 1.002-1018, P = 0.0169), while differential survival of females was not significantly predicted by this factor (P = 0.7639). Conclusions: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status. These results suggest that the influence of smoking habit on responsiveness to gefitinib is gender specific.
| Original language | English |
|---|---|
| Pages (from-to) | 117-123 |
| Number of pages | 7 |
| Journal | Journal of Cancer Research and Clinical Oncology |
| Volume | 135 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2009 |
Fingerprint
Keywords
- Gefitinib
- Gender
- Non-small-cell lung cancer
- Objective response
- Smoking status
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung : Okayama Lung Cancer Study Group experience. / Hotta, Katsuyuki; Kiura, Katsuyuki; Takigawa, Nagio; Kuyama, Shoichi; Segawa, Yoshihiko; Yonei, Toshiro; Gemba, Kenichi; Aoe, Keisuke; Shibayama, Takuo; Matsuo, Keisuke; Kamei, Haruhito; Fujiwara, Yoshiro; Bessho, Akihiko; Moritaka, Tomonori; Sugimoto, Keisuke; Tabata, Masahiro; Ueoka, Hiroshi; Tanimoto, Mitsune.
In: Journal of Cancer Research and Clinical Oncology, Vol. 135, No. 1, 01.2009, p. 117-123.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung
T2 - Okayama Lung Cancer Study Group experience
AU - Hotta, Katsuyuki
AU - Kiura, Katsuyuki
AU - Takigawa, Nagio
AU - Kuyama, Shoichi
AU - Segawa, Yoshihiko
AU - Yonei, Toshiro
AU - Gemba, Kenichi
AU - Aoe, Keisuke
AU - Shibayama, Takuo
AU - Matsuo, Keisuke
AU - Kamei, Haruhito
AU - Fujiwara, Yoshiro
AU - Bessho, Akihiko
AU - Moritaka, Tomonori
AU - Sugimoto, Keisuke
AU - Tabata, Masahiro
AU - Ueoka, Hiroshi
AU - Tanimoto, Mitsune
PY - 2009/1
Y1 - 2009/1
N2 - Background: Gefitinib is effective in patients with lung adenocarcinoma. Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma. Methods: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known. Tumour response and survival were evaluated and stratified by smoking status and gender. Results: Among the 260 patients, 157 were male (60%). Median pack-years was 40 (range 8-160) and 23 (range 1-74) in male and female smokers, respectively. Objective response was observed in 62 (23.8%) of the 260 patients, and 1-year overall survival and progression-free survival were 45.1 and 24.3%, respectively. Multivariate analysis revealed that smoking status (pack-years) was an independent predictive factor for response to gefitinib [odds ratio (OR) = 0.971, 95% confidence interval (CI) = 0.947-0.995; P = 0.0159] in male patients, but not in female patients (OR = 0.999, 95%CI = 0.957-1.042). Additionally, pack-years significantly influenced the overall survival in males (hazard ratio = 1.010; 95%CI = 1.002-1018, P = 0.0169), while differential survival of females was not significantly predicted by this factor (P = 0.7639). Conclusions: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status. These results suggest that the influence of smoking habit on responsiveness to gefitinib is gender specific.
AB - Background: Gefitinib is effective in patients with lung adenocarcinoma. Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma. Methods: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known. Tumour response and survival were evaluated and stratified by smoking status and gender. Results: Among the 260 patients, 157 were male (60%). Median pack-years was 40 (range 8-160) and 23 (range 1-74) in male and female smokers, respectively. Objective response was observed in 62 (23.8%) of the 260 patients, and 1-year overall survival and progression-free survival were 45.1 and 24.3%, respectively. Multivariate analysis revealed that smoking status (pack-years) was an independent predictive factor for response to gefitinib [odds ratio (OR) = 0.971, 95% confidence interval (CI) = 0.947-0.995; P = 0.0159] in male patients, but not in female patients (OR = 0.999, 95%CI = 0.957-1.042). Additionally, pack-years significantly influenced the overall survival in males (hazard ratio = 1.010; 95%CI = 1.002-1018, P = 0.0169), while differential survival of females was not significantly predicted by this factor (P = 0.7639). Conclusions: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status. These results suggest that the influence of smoking habit on responsiveness to gefitinib is gender specific.
KW - Gefitinib
KW - Gender
KW - Non-small-cell lung cancer
KW - Objective response
KW - Smoking status
UR - http://www.scopus.com/inward/record.url?scp=56649123403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649123403&partnerID=8YFLogxK
U2 - 10.1007/s00432-008-0431-1
DO - 10.1007/s00432-008-0431-1
M3 - Article
C2 - 18618142
AN - SCOPUS:56649123403
VL - 135
SP - 117
EP - 123
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
SN - 0171-5216
IS - 1
ER -